Edward J Wild

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5708334/publications.pdf

Version: 2024-02-01

131 papers	11,580 citations	50244 46 h-index	30894 102 g-index
140 all docs	140 docs citations	140 times ranked	9988 citing authors

#	Article	IF	Citations
1	Huntington disease. Nature Reviews Disease Primers, 2015, 1, 15005.	18.1	1,031
2	Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology, 2014, 10, 204-216.	4.9	873
3	Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurology, The, 2009, 8, 791-801.	4.9	856
4	Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurology, The, 2013, 12, 637-649.	4.9	704
5	A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. Journal of Experimental Medicine, 2008, 205, 1869-1877.	4.2	559
6	Targeting Huntingtin Expression in Patients with Huntingtonâ€™s Disease. New England Journal of Medicine, 2019, 380, 2307-2316.	13.9	493
7	Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurology, The, 2012, 11, 42-53.	4.9	479
8	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	4.5	455
9	CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology, 2012, 78, 690-695.	1.5	303
10	Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. Lancet Neurology, The, 2017, 16, 601-609.	4.9	272
11	C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology, 2014, 82, 292-299.	1.5	252
12	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Lancet Neurology, The, 2017, 16, 701-711.	4.9	248
13	Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nature Reviews Neurology, 2020, 16, 529-546.	4.9	248
14	Therapies targeting DNA and RNA in Huntington's disease. Lancet Neurology, The, 2017, 16, 837-847.	4.9	233
15	Proteomic Profiling of Plasma in Huntington's Disease Reveals Neuroinflammatory Activation and Biomarker Candidates. Journal of Proteome Research, 2007, 6, 2833-2840.	1.8	212
16	Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntingtonâ€™s disease patients. Journal of Clinical Investigation, 2015, 125, 1979-1986.	3.9	209
17	Rapid Eye Movement Sleep Disturbances in Huntington Disease. Archives of Neurology, 2008, 65, 482.	4.9	197
18	Huntington's disease phenocopy syndromes. Current Opinion in Neurology, 2007, 20, 681-687.	1.8	146

#	Article	IF	Citations
19	Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntingtonâ€™s disease. Science Translational Medicine, 2018, 10, .	5.8	134
20	Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. Brain, 2008, 131, 2851-2859.	3.7	127
21	Observing Huntingtonâ€™s Disease: the European Huntingtonâ€™s Disease Networkâ€™s REGISTRY. PLOS Currents, 2010, 2, RRN1184.	1.4	124
22	Mutant huntingtin fragmentation in immune cells tracks Huntingtonâ€™s disease progression. Journal of Clinical Investigation, 2012, 122, 3731-3736.	3.9	123
23	Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis. Lancet Neurology, The, 2020, 19, 502-512.	4.9	122
24	Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease. Human Molecular Genetics, 2011, 20, 1937-1951.	1.4	121
25	Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 14424-14429.	3.3	120
26	Brain-Derived Neurotrophic Factor in Patients with Huntington's Disease. PLoS ONE, 2011, 6, e22966.	1.1	118
27	Targets for future clinical trials in Huntington's disease: What's in the pipeline?. Movement Disorders, 2014, 29, 1434-1445.	2.2	116
28	Huntington's disease phenocopies are clinically and genetically heterogeneous. Movement Disorders, 2008, 23, 716-720.	2.2	108
29	The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 756-763.	0.9	105
30	Abnormal peripheral chemokine profile in Huntingtonâ€™s disease. PLOS Currents, 2011, 3, RRN1231.	1.4	96
31	Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities. Lancet Neurology, The, 2022, 21, 645-658.	4.9	96
32	Pitfalls in the Use of Voxel-Based Morphometry as a Biomarker: Examples from Huntington Disease. American Journal of Neuroradiology, 2010, 31, 711-719.	1.2	94
33	Defective emotion recognition in early HD is neuropsychologically and anatomically generic. Neuropsychologia, 2008, 46, 2152-2160.	0.7	93
34	Onset and Progression of Pathologic Atrophy in Huntington Disease: A Longitudinal MR Imaging Study. American Journal of Neuroradiology, 2010, 31, 1036-1041.	1.2	90
35	Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease. Neurology, 2009, 73, 1280-1285.	1.5	84
36	Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1409-1412.	0.9	82

#	Article	IF	Citations
37	The differential diagnosis of chorea. Practical Neurology, 2007, 7, 360-373.	0.5	80
38	Dï¿½jï¿½ vu in neurology. Journal of Neurology, 2005, 252, 1-7.	1.8	77
39	Suicidal ideation in a European Huntington's disease population. Journal of Affective Disorders, 2013, 151, 248-258.	2.0	74
40	Neurofilament light protein in blood predicts regional atrophy in Huntington disease. Neurology, 2018, 90, e717-e723.	1.5	65
41	Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntingtonâ€™s disease. Science Translational Medicine, 2020, 12, .	5.8	64
42	Cerebrospinal Fluid Biomarkers for Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2016, 5, 1-13.	0.9	60
43	Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease. Journal of Neurochemistry, 2016, 139, 22-25.	2.1	58
44	Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntingtonâ€™s Disease. PLoS ONE, 2016, 11, e0163479.	1.1	58
45	Huntingtonâ€™s Disease Clinical Trials Corner: February 2018. Journal of Huntington's Disease, 2018, 7, 89-98.	0.9	56
46	Relationship between CAG repeat length and brain volume in premanifest and early Huntingtonâ€™s disease. Journal of Neurology, 2009, 256, 203-212.	1.8	50
47	Wholeâ€brain atrophy as a measure of progression in premanifest and early Huntington's disease. Movement Disorders, 2009, 24, 932-936.	2.2	49
48	The V471A Polymorphism in Autophagy-Related Gene ATG7 Modifies Age at Onset Specifically in Italian Huntington Disease Patients. PLoS ONE, 2013, 8, e68951.	1.1	49
49	Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntingtonâ€™s disease R6/2 mice. Scientific Reports, 2017, 7, 14114.	1.6	49
50	Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?. Movement Disorders Clinical Practice, 2017, 4, 582-585.	0.8	48
51	Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay. Journal of Huntington's Disease, 2017, 6, 349-361.	0.9	48
52	Huntingtonâ€™s Disease Clinical Trials Corner: April 2020. Journal of Huntington's Disease, 2020, 9, 185-197.	0.9	47
53	Automated quantification of caudate atrophy by local registration of serial MRI: Evaluation and application in Huntington's disease. NeuroImage, 2009, 47, 1659-1665.	2.1	46
54	Fluid and imaging biomarkers for Huntington's disease. Molecular and Cellular Neurosciences, 2019, 97, 67-80.	1.0	41

#	Article	IF	Citations
55	Huntingtonâ€™s disease mice and human brain tissue exhibit increased G3BP1 granules and TDP43 mislocalization. Journal of Clinical Investigation, 2021, 131, .	3.9	38
56	Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease. Journal of Neuroscience, 2021, 41, 780-796.	1.7	37
57	Harnessing Immune Alterations in Neurodegenerative Diseases. Neuron, 2009, 64, 21-24.	3.8	36
58	Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series. Molecular Psychiatry, 2020, 25, 3399-3412.	4.1	34
59	Neuropsychiatry and White Matter Microstructure in Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2015, 4, 239-249.	0.9	33
60	Clinical Trials Corner: September 2017. Journal of Huntington's Disease, 2017, 6, 255-263.	0.9	33
61	George Huntington: a legacy of inquiry, empathy and hope. Brain, 2016, 139, 2326-2333.	3.7	31
62	Huntingtonâ€™s Disease Clinical Trials Corner: June 2019. Journal of Huntington's Disease, 2019, 8, 363-371.	0.9	30
63	Corpus Callosal Atrophy in Premanifest and Early Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 517-526.	0.9	29
64	The use of wearable/portable digital sensors in Huntington's disease: A systematic review. Parkinsonism and Related Disorders, 2021, 83, 93-104.	1.1	28
65	Cerebrospinal fluid neurogranin and TREM2 in Huntingtonâ€™s disease. Scientific Reports, 2018, 8, 4260.	1.6	25
66	Serial volumetric MRI in Parkinsonian disorders. Movement Disorders, 2009, 24, S691-8.	2.2	24
67	Huntingtonâ€™s Disease Clinical Trials Corner: January 2019. Journal of Huntington's Disease, 2019, 8, 115-125.	0.9	23
68	Predict-HD and the future of therapeutic trials. Lancet Neurology, The, 2006, 5, 724-725.	4.9	22
69	Huntingtonâ€™s Disease Clinical Trials Corner: August 2018. Journal of Huntington's Disease, 2018, 7, 279-286.	0.9	22
70	Biofluid Biomarkers in Huntingtonâ€™s Disease. Methods in Molecular Biology, 2018, 1780, 329-396.	0.4	21
71	Discrepancies in reporting the CAG repeat lengths for Huntington's disease. European Journal of Human Genetics, 2012, 20, 20-26.	1.4	20
72	Characterizing White Matter in Huntington's Disease. Movement Disorders Clinical Practice, 2020, 7, 52-60.	0.8	20

#	Article	IF	Citations
73	NMDA receptor gene variations as modifiers in Huntington disease: a replication study. PLOS Currents, 2011, 3, RRN1247.	1.4	20
74	Rate and acceleration of whole-brain atrophy in premanifest and early Huntington's disease. Movement Disorders, 2010, 25, 888-895.	2.2	19
75	Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease. Journal of Neurochemistry, 2021, 158, 539-553.	2.1	18
76	Plasma neurofilament heavy chain levels in Huntington's disease. Neuroscience Letters, 2007, 417, 231-233.	1.0	16
77	Immune markers for Huntingtonâ€™s disease?. Expert Review of Neurotherapeutics, 2008, 8, 1779-1781.	1.4	16
78	Huntingtonâ€™s Disease Clinical Trials Corner: April 2022. Journal of Huntington's Disease, 2022, 11, 105-118.	0.9	16
79	JAK/STAT Signalling in Huntingtonâ€™s Disease Immune Cells. PLOS Currents, 2013, 5, .	1.4	15
80	A Remote Digital Monitoring Platform to Assess Cognitive and Motor Symptoms in Huntington Disease: Cross-sectional Validation Study. Journal of Medical Internet Research, 2022, 24, e32997.	2.1	15
81	Comparison of the Huntington's Disease like 2 and Huntington's Disease Clinical Phenotypes. Movement Disorders Clinical Practice, 2019, 6, 302-311.	0.8	14
82	Quantification of huntingtin protein species in Huntingtonâ€™s disease patient leukocytes using optimised electrochemiluminescence immunoassays. PLoS ONE, 2017, 12, e0189891.	1.1	14
83	Meta-research metrics matter: letter regarding article â€œindirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington diseaseâ€. Journal of Clinical Movement Disorders, 2017, 4, 19.	2.2	13
84	Vasculitic Presentation of Staphylococcal Meningitis. Archives of Neurology, 2007, 64, 1788.	4.9	12
85	Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntingtonâ€™s disease. Scientific Reports, 2021, 11, 3481.	1.6	12
86	Biomarkers for Huntington's disease. Expert Opinion on Medical Diagnostics, 2008, 2, 47-62.	1.6	9
87	Biomarkers for Huntington's disease: an update. Expert Opinion on Medical Diagnostics, 2012, 6, 371-375.	1.6	9
88	Premanifest and Early Huntingtonâ€™s Disease. , 2014, , .		9
89	Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children. Movement Disorders, 2022, 37, 1526-1531.	2.2	9
90	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. PLoS ONE, 2020, 15, e0233820.	1.1	8

#	Article	IF	Citations
91	Neuropsychiatric comorbidities in Huntingtonâ€™s and Parkinsonâ€™s Disease: A United States claims database analysis. Annals of Clinical and Translational Neurology, 2021, 8, 126-137.	1.7	8
92	One decade ago, one decade ahead in huntington's disease. Movement Disorders, 2019, 34, 1434-1439.	2.2	7
93	Safety and Feasibility of Research Lumbar Puncture in Huntingtonâ€™s Disease: The HDClarity Cohort and Bioresource. Journal of Huntington's Disease, 2022, 11, 59-69.	0.9	7
94	The domino inequalities: facets for the symmetric traveling salesman polytope. Mathematical Programming, 2003, 98, 223-251.	1.6	6
95	HDBuzz: empowering patients through accessible education. Trends in Molecular Medicine, 2012, 18, 1-3.	3.5	6
96	Huntington's Disease: The Most Curable Incurable Brain Disorder?. EBioMedicine, 2016, 8, 3-4.	2.7	6
97	Natural history and burden of Huntington's disease in the <scp>UK</scp>: A <scp>population‐based</scp> cohort study. European Journal of Neurology, 2022, 29, 2249-2257.	1.7	6
98	Cerebrospinal fluid flow dynamics in Huntington's disease evaluated by phase contrast <scp>MRI</scp>. European Journal of Neuroscience, 2019, 49, 1632-1639.	1.2	5
99	Psychogenic non-epileptic seizures in early Huntington's disease. Practical Neurology, 2016, 16, 452-454.	0.5	4
100	D1â€…HDClarity: a multi-site cerebrospinal fluid collection initiative to facilitate therapeutic development for huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A34.1-A34.	0.9	3
101	F61â€…Digital, high-frequency, long-term monitoring of motor and non-motor symptoms in huntingtonâ€™s disease (hd) patients. , 2018, , .		3
102	Estimating the causal effects of modifiable, non-genetic factors on Huntington disease progression using propensity score weighting. Parkinsonism and Related Disorders, 2021, 83, 56-62.	1.1	3
103	<scp>CAG</scp> Somatic Instability in a Huntington Disease Expansion Carrier Presenting with a Progressive Supranuclear Palsy‐like Phenotype. Movement Disorders, 2022, 37, 1555-1557.	2.2	3
104	Huntington's disease: fighting on many fronts. Brain, 2012, 135, 998-1001.	3.7	2
105	Perinatal insults and neurodevelopmental disorders may impact Huntington's disease age of diagnosis. Parkinsonism and Related Disorders, 2018, 55, 55-60.	1.1	2
106	J01â€…Effects of IONIS-HTTRX (RG6042) in patients with early huntingtonâ€™s disease, results of the first htt-lowering drug trial. , 2018, , .		2
107	Thyrotoxic periodic paralysis in a Maori patient. New Zealand Medical Journal, 2004, 117, U1204.	0.5	2
108	Huntington's disease. , 0, , 64-82.		1

#	Article	IF	Citations
109	QUANTIFYING MUTANT HUNTINGTIN IN HUNTINGTON'S DISEASE CSF. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.132-e4.	0.9	1
110	Ghost Pills: A Case Report. Annals of Internal Medicine, 2017, 166, 609.	2.0	1
111	Nonlinear Elastic Spline Registration: Evaluation with Longitudinal Huntingtonâ€™s Disease Data. Lecture Notes in Computer Science, 2010, , 128-139.	1.0	1
112	F06â€…A critical evaluation of inflammatory markers in Huntington's disease plasma. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, A23.1-A23.	0.9	0
113	F05â€…Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, A22.3-A23.	0.9	0
114	D01 Quantification Of Huntingtin Species In Huntington's Disease Patient Leukocytes Using Electrochemiluminescence Immunoassays. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, A31-A32.	0.9	0
115	K4â€…The cost and value of a huntingtonâ€™s disease multidisciplinary team meeting. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A80.2-A80.	0.9	0
116	D4â€…Prediction of huntingtonâ€™s disease phenotype by cerebrospinal fluid biomarkers of inflammation and cell death. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A35.1-A35.	0.9	0
117	J9â€…Probing huntingtonâ€™s disease phenocopy syndromes with next-generation sequencing. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A78.2-A78.	0.9	0
118	PO002â€…Bacterial meningitis with myelopathy and cranial neuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A13.2-A13.	0.9	0
119	D10â€…Neurofilament light protein in blood predicts regional atrophy in huntingtonâ€™s disease. , 2018, , .		0
120	D09â€…Parallel evaluation of mutant huntingtin and neurofilament light as biomarkers for huntingtonâ€™s disease: the hd-csf study. , 2018, , .		0
121	F10â€…Environmental modifiers of huntingtonâ€™s disease: using propensity scores and outcome analyses to identify causal links. , 2018, , .		0
122	Physician perception versus true efficacy of tetrabenazine for Huntingtonâ€™s disease. Current Medical Research and Opinion, 2018, 34, 1537-1538.	0.9	0
123	F05â€…Biological and clinical characteristics of gene carriers far from predicted onset in the hd-yas study: a cross-sectional analysis. , 2021, , .		0
124	Huntingtonâ€™s Disease Look-alikes. , 2013, , 223-230.		0
125	E07â€…Cerebrospinal fluid flow dynamics in huntingtonâ€™s disease using phase contrast MRI: a pilot cross-sectional study. , 2018, , .		0
126	D08â€…Neurofilament light protein in blood as a potential biomarker of neurodegeneration in hungtingtonâ€™s disease: a retrospective cohort analysis. , 2018, , .		0

#	Article	IF	Citations
127	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. , 2020, 15, e0233820.		0
128	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. , 2020, 15, e0233820.		0
129	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. , 2020, 15, e0233820.		0
130	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. , 2020, 15, e0233820.		0
131	241â€… Intrathecal antisense oligonucleotide delivery in HD: experience from RG6042 programme and best practice considerations. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A83.1-A83.	0.9	0